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Abstract
Background: Previously the angiotensin II receptor blocker Irbesartan has been demonstrated to reduce the risk
for progression from microalbuminuria to macroalbuminuria in type 2 diabetic patients. The purpose of this study
was to evaluate the effect of treatment with Irbesartan in type 2 diabetic patients with microalbuminuria on the
urinary proteome.
Methods: High-resolution capillary-electrophoresis coupled to mass-spectrometry (CE-MS) was used to profile the
low-molecular-weight proteome in urine of a subgroup of patients from a two year randomized irbesartan versus
placebo therapy trial, which included hypertensive type 2 diabetic patients with microalbuminuria on ongoing
antihypertensive medication (IRMA2-substudy).
Results: We demonstrate that the therapy with 300 mg Irbesartan daily over a period of two years results in
significant changes of the urinary proteome. Both, a classifier developed previously that consists of urinary peptides
indicative of chronic kidney disease, as well as several individual peptides changed significantly after treatment.
These changes were not observed in the placebo-treated individuals. Most prominent are changes of urinary
collagen fragments associated with progression of diabetic nephropathy, indicating normalization in urinary
peptides.
Conclusion: CE-MS analysis of urine enabled identification of peptides as potential surrogate markers for
renoprotection in microalbuminuric type 2 diabetic patients, which show persistent improvement after longterm
treatment with Irbesartan. The results suggest that a major benefit of treatment by Irbesartan may be improvement
of collagen turnover, reduction of fibrosis. They further suggest that urinary proteome analysis could be utilized to
assess potential benefit of therapeutic intervention, providing statistically significant results even on a small
population.
Background
At present more than 170 million people worldwide
have diabetes and the number is expected to double
within the next 20 years mainly due to an epidemic
increase in the prevalence of type 2 diabetes [1]. Type 2
diabetes is associated with an increased occurrence of
cardiovascular disease and approximately 40% of all dia-
betic patients are at risk of developing diabetic nephro-
pathy which has become the leading cause of end-stage
renal disease (ESRD) in the Western world [2].
Therefore, the early identification and subsequent end-
organ protective treatment of all patients at risk for
ESRD is of outmost importance. Patients with persistent
microalbuminuria [urinary albumin excretion (UAE)
between 30 and 300 mg/24 hours] have a 10 to 20 times
increased risk of developing diabetic nephropathy as
compared to patients with normoalbuminuria [2]. In
addition, the occurrence of microalbuminuria is asso-
ciated with an increased risk of premature death due to
cardiovascular disease [3].
Reduction of UAE by blockade of the renin-angioten-
sin-aldosterone system (RAAS) has emerged as a key
treatment goal for both reno- and cardiovascular protec-
tion [4,5]. Data from the large clinical “Irbesartan in
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(IRMA2) study [6] firmly demonstrated that treatment
with the angiotensin II receptor blocker (ARB) Irbesar-
tan, 300 mg once daily, reduces UAE and the risk of
progression to overt diabetic nephropathy in hyperten-
sive patients with type 2 diabetes and persistent microal-
buminuria. Furthermore, in type 2 diabetic patients with
more advanced renal disease, ARBs have been shown to
reduce the risk of reaching the combined renal end
point of doubling in serum creatinine, ESRD, or death
[5,7]. Since 2002, ARBs have consequently been recom-
mended as first-line therapy in hypertensive type 2 dia-
betic patients with microalbuminuria or overt diabetic
nephropathy according to guidelines from the American
Diabetes Association [8].
Recently, we and others demonstrated that diabetic
nephropathy and chronic renal disease in general are
reflected by specific peptides and proteins in urine
[9-24], and the human urinary proteome has been
extensively investigated to gain insight about disease
processes affecting the kidney and the urogenital tract
[12,25-28]. Urinary proteins and peptides originate not
only from glomerular filtration, but also from tubular
secretion, epithelial cells shed from the kidney and urin-
ary tract, secreted exosomes [29], and seminal secretions
[30-32]. Thus, in principle, urine is a rich source of bio-
markers for a wide range of diseases due to specific
changes in its proteome [33-36]. Urine is a preferred
body fluid for proteome analysis, as it is quite stable,
probably due to the fact that it is “stored” for hours in
t h eb l a d d e r ,h e n c ep r o t e o l y t i cd e g r a d a t i o nb ye n d o g e n -
ous proteases, a major obstacle in proteomics studies
f o c u s i n go nb l o o d[ 3 7 ] ,m a yb ee s s e n t i a l l yc o m p l e t eb y
the time of voiding [38,39]. This also enabled the estab-
lishment of human urine reference standard samples
[40]. In pilot studies aiming toward differential diagnosis
of certain types of CKD we could show that several pep-
tides are differentially excreted in the urine of patients
with different chronic kidney diseases compared to
healthy individuals [41,42]. An optimized protocol for
sample preparation and analysis has been developed,
that includes removal of proteins above 25 kDa without
significant loss of low-molecular-weight urinary compo-
nents [43]. Using this protocol, urinary biomarkers
enabling differential diagnosis of specific single chronic
renal diseases (IgA nephropathy, diabetic nephropathy,
and ANCA-associated vasculitis) with good sensitivity
and specificity in blinded data-sets could be identified
[13,19,21,44]. Employing previously established biomar-
kers and biomarker patterns as classifiers [19,20], we
investigated if a therapeutic benefit of Irbesartan in
microalbuminuric type 2 diabetes patients can by dis-
played by proteomic changes in urine. In addition, we
aimed at identifying those peptides that show significant
changes upon Irbesartan treatment, as these may reveal
further insights into the pathophysiology of disease, and
allow assessment of therapeutic efficacy.
Methods
Patient characteristics
Spontaneously voided urine samples were collected from
type 2 diabetic patients followed at Steno Diabetes Center
as a subset of the ‘IRMA2’ study described previously [45].
The study was in compliance with the Helsinki Declaration
and all patients gave written informed consent. The study
was approved by the ethics committee of Copenhagen
County KA 97015 gms. Samples from all patients included
in the study receiving either Irbesartan in a dose of 300 mg
once daily or placebo were employed for CE-MS analysis,
if samples were available from both, baseline and after two
years of treatment. As the effect of a dose of 150 mg once
daily was not significant on UAER, in the IRMA2 study, we
only used 300 mg daily and compared with placebo. In
total, samples from 22 patients (11 irbesartan and 11 pla-
cebo) were available. At baseline 2 patients in the placebo
and 4 in the irbesartan group were treated with insulin,
after 2 years it was 5 and 4. Unchanged throughout the
study, 8 patients in the placebo and 6 in the irbesartan
group were treated with oral hypoglycemic agents at base-
line, 3 patients in each group were treated with a statin at
baseline, 8 patients in the placebo and 5 in the irbesartan
group were treated with aspirin for cardiovascular protec-
tion at baseline. Demographic data of the patients included
are shown in Additional file 1, spreadsheet: ‘patient data’.
Sample preparation
Samples consisted of overnight urines, stored in aliquots
at -20°C for 8-12 years, which were prepared essentially
as described [46]. A 0.7 mL aliquot was thawed immedi-
ately before use and diluted with 0.7 mL 2 M urea, 10
mM NH4OH containing 0.02 % SDS. In order to
remove high molecular weight polypeptides, samples
were filtered using Centrisart ultracentrifugation filter
devices (20 kDa molecular weight cut-off; Sartorius,
Goettingen, Germany) at 3,000 g until 1.1 mL of filtrate
was obtained. Subsequently, filtrate was desalted using
PD-10 column (GE Healthcare, Sweden) equilibrated in
0.01% NH4OH in HPLC-grade water. Finally, samples
were lyophilized and stored at 4°C. This procedure
results in an average recovery of sample in the prepara-
tion procedure ~85% [21]. Shortly before CE-MS analy-
sis, lyophilisates were resuspended in HPLC-grade water
to a final protein concentration of 0.8 μg/μL checked by
BCA assay (Interchim, Montlucon, France).
CE-MS analysis
CE-MS analysis was performed as previously described
[37,47]. The limit of detection was ~1 fmol, mass
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sotopic mass signals for z≤ 6. After charge deconvolu-
tion, mass deviation was < 25 ppm for monoisotopic
resolution and < 100 ppm for unresolved peaks (z > 6).
The analytical precision of the platform was assessed by
(a) reproducibility achieved for repeated measurement
of the same replicate and (b) by the reproducibility
achieved for repeated preparation and measurement of
the same urine sample; details on analytical precision
were reported recently [21]. To ensure high data consis-
tency, a minimum of 950 peptides/proteins had to be
detected with a minimal MS resolution of 8,000 in a
minimal migration time interval of 10 minutes.
Data processing
Mass spectral ion peaks representing identical molecules
at different charge states were deconvoluted into single
masses using MosaiquesVisu software [48]. Both CE-
migration time and ion signal intensity (amplitude)
show variability, mostly due to different concentration
of ions in the sample, and are consequently normalized.
Reference signals of 1770 urinary polypeptides are used
for CE-time calibration by local regression. For normali-
zation of analytical and urine dilution variances, MS sig-
nal intensities are normalized relative to 29
“housekeeping” peptides generally present in at least
90% of all urine samples with small relative standard
deviation. For calibration, local regression is performed
[49]. The obtained peak lists characterize each polypep-
tide by its molecular mass [Da], normalized CE migra-
tion time [min] and normalized signal intensity. All
detected peptides were deposited, matched, and anno-
tated in a Microsoft SQL database allowing further sta-
tistical analysis.
Data analysis
The datasets were examined either with respect to sig-
nificant changes in single, predefined peptides and with
respect to scoring in biomarker models (see Additional
file 1, spreadsheet: ‘classification factor’). These biomar-
ker models consist of 65 or 273 biomarkers respectively,
which were previously found to be significantly associ-
ates with diabetic nephropathy [19] or chronic kidney
disease [20].
For the application of the previously established bio-
marker patterns, Wilcoxon test (for paired samples) was
performed to receive Box-and-Whisker plots and dot-
and-line diagrams [50] (MedCalc version 8.1.1.0, Med-
Calc Software, Belgium, http://www.medcalc.be).
For multiple testing corrections, p-values were cor-
rected using the false discovery rate procedure intro-
duced by Benjamini and Hochberg, [51]. To eliminate
sporadic findings, only proteins that were detected in a
diagnostic group of patients in at least 50% of samples
were considered.
Results
Samples from 22 patients included in the IRMA2 trial,
where urine was collected at baseline before treatment
(visit 2) and after two years treatment (visit 9) with Irbe-
sartan or placebo, were analyzed. All available samples
were included in the study, and analyzed using CE-MS,
no additional specimens that fit the criteria (2 years fol-
low up, placebo or 300 mg Irbesartan daily) are available
from the IRMA2 trial. All samples analyzed passed the
threshold of the quality control criteria given in the
Methods section, no significant deterioration of peptides
d u et os t o r a g ec o u l db eo b s e r v e d .T h ed a t af r o ma l l
analyses are presented in the Additional file 1. As
shown in figure 1, the compiled data of these 4 groups
disclosed first insights into changes of the urinary pro-
teome, where high concentrations of some peptides
decreased with Irbesartan intake. To assess the relevance
of any proteomics changes with respect to diabetic
nephropathy, we applied already established polypeptide
patterns onto these data.
First, data from patients that received ARB treatment
were evaluated applying a biomarker pattern indicative
for diabetic nephropathy [19]. This analysis revealed no
significant differences (p = 0.175) between these two
groups of patients (visit 2 and visit 9) using Wilcoxon-
test for paired samples (data not shown). However, the
DN pattern was developed employing samples from dia-
betes type 1 patients treated with ARB [19], hence may
not be applicable for type 2 diabetic patients, and may
further be inappropriate to reflect drug-induced
changes.
We therefore also employed a polypeptide pattern
indicative of chronic kidney disease (CKD), that consist
of 273 known peptides [20] for the classification of the
urine samples from the ‘IRMA2’ study. This model is
based on the CE-MS analysis of urine samples from 340
patients with CKD of different etiologies (including focal
segmental glomerulosclerosis, membranous glomerulo-
nephritis, minimal change disease, IgA nephropathy, sys-
temic lupus erythematosus, ANCA-associated vasculitis,
and diabetic nephropathy) and 550 controls (healthy
individuals as well as patients without any evidence for
renal diseases). Figure 2 demonstrates the changes of
these 273 peptides of the CKD model before and after
treatment with Irbesartan and placebo, respectively.
While the peptide pattern of the ARB treated patients is
similar to that observed for diabetic nephropathy (com-
pare Figure 1 in [19]) at the beginning of the study
(prior treatment), it changed towards higher similarity
to normalbuminuric subjects after 2 years of Irbesartan
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figure 3A, this classification resulted in a significant
(p = 0.0244) decline of the median classification factor
(indicating an improvement of the kidney physiology),
which was reduced (from 0.721 at visit 2 to 0.277 at
visit 9) below the established cut-off (0.343) of the CKD
model. Irrespective of the values before Irbesartan
intake, the classification factors were decreasing during
Irbesartan treatment in all patients except one (see fig-
ure 3B). This patient progressed to DN several years
after the end of the study, none of the eleven patients
developed macroalbuminuria during the two year study
period. In the urine samples of the eleven patients trea-
ted with placebo, a non significant (p = 0.1016) increase
(indicating a change towards “chronic kidney disease”)
of the median classification factor (see figure 3C) from
-0.104 at visit 2 to 0.188 at visit 9 could be observed.
Although many patients of the placebo-group scored
lower than those of the Irbesartan-group at baseline
before treatment (see figure 3B and 3D), the classifica-
tion factor of most placebo-treated patients was higher
after two years, as expected for progressing disease.
We subsequently investigated which of the 273 biomar-
kers that were found significantly associated with CKD
undergo significant changes upon Irbesartan treatment.
Eighteen of these CKD markers showed significant differ-
ences (p < 0.05) in urine of patients before and after 2-
year treatment with Irbesartan (see table 1). Of these 18,
Figure 1 Polypeptide patterns of patients with diabetes type 2 before and after 2-year treatment (Irbesartan and placebo) examined
in the ‘IRMA2’ study. Shown are compiled patterns consisting of all samples from each of the four groups. The molecular mass (0.7 to 15 kDa,
on a logarithmic scale) is plotted against normalized migration time (17 to 47 min). Signal intensity is encoded by peak height and color.
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ble benefit of therapy. Seven changes towards “chronic
kidney disease”, possibly indicating progression of patho-
physiological changes over time that is not affected by
therapy. We also investigated the 273 biomarkers in the
placebo group. Here, we found 7 CKD markers which
show significant differences within the 2-year treatment.
Of these 7 peptides, all changed toward “disease”.I n
total, 23 urinary CKD markers showed significant
changes over the period of two years, either in the
patients of the Irbesartan group or in the placebo group,
2 were significant in both groups. These two CKD mar-
kers, both collagen alpha-1 fragments (see table 1, bold
letters), showed significant change towards “healthy” in
the Irbesartan group and opposite regulation in the
placebo group over the period of two years. While the
amount of these two collagen fragments increased signifi-
cantly in the ARB group (indicating an improvement
towards “healthy”), their abundance was significantly
decreased after 2 years of placebo treatment, indicating
further progression of chronic kidney disease.
T oo b t a i ni n f o r m a t i o no na d d i t i o n a lc h a n g e si nt h e
urinary proteome associated with Irbesatan treatment
beyond those observed for the previously defined CKD
biomarkers, we examined the data on all sequenced pep-
tides [40,52] for significant changes between baseline
and 2-year treatment (in each group; Irbesartan and pla-
cebo). We could not identify additional biomarkers,
which revealed significant changes between baseline and
2-year treatment.
Figure 2 Peptide patterns of 273 CKD marker used for the proteomic analysis of patients from the ‘IRMA2’ subgroup. The compiled
data sets of urine samples from patients derived from the ‘IRMA2 study’ before and after 2-year treatment of Irbesartan (upper panel) as well as
placebo (lower panel) are shown. Normalized molecular mass (y-axis) is plotted against normalized CE-migration time (x-axis). The mean signal
intensity is represented in 3D-depiction.
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In the IRMA2 study a 300 mg daily dose of the angio-
tensin II receptor blocker Irbesartan significantly
reduced albuminuria compared to placebo [6]. Using
CE-MS analysis of urine in all available samples (a sub-
set of 22 of these patients) we were able to demonstrate
a persistent and significant changes of the previously
established proteomic CKD classifier [20] towards
“healthy”. After long-term renoprotective treatment with
Irbesartan. Furthermore, the proteomic analysis of pla-
cebo treated patients showed a slight, yet not significant,
increase of this classifier. This increase likely reflects
disease progression in the absence of appropriate ther-
apy, like blocking the renin angiotensin system demon-
strated to protect against development of diabetic
nephropathy.
We have previously reported that collagen fragments
are reduced in patients with diabetic nephropathy [19].
After confirmation in additional samples, we generated
the hypothesis that this reduction in urinary collagen
fragments may be an indicator of attenuated collagen
breakdown, resulting in fibrosis [53]. The results
presented here further indicate that this process may be
positively influenced by ARB treatment, resulting in an
increase in urinary collagen fragments, likely reflecting
an increase of proteolysis towards normal ("healthy”)
physiological levels. It is tempting to speculate that the
urinary proteomic changes observed here may be a con-
sequence of an actual change in renal pathophysiology,
and not merely a consequence of the changes in urine
protein concentration. To substantiate this hypothesis,
analysis of longitudinal samples on a larger cohort will
be undertaken.
As we also could show recently, the collagen frag-
ments have similar quality as biomarkers in both, 24 h
and spot urine [49]. This is to be expected since their
secretion into urine does not appear to change signifi-
cantly during the day (Mischak, unpublished), and the
concentration of these biomarkers is assessed in refer-
ence to internal standards, in a similar way as albumin/
creatinine ratio.
The changes in the urinary proteome reported here
were observed employing a biomarker pattern that is
associated with CKD in general, not restricted to
Figure 3 Classification results of the ‘IRMA2’ patient samples, classified with the CKD model [20]. A) Box-and-Whisker plot of
microalbuminuric patients before (visit 2) and after two years (visit 9) treatment with 300 mg Irbesartan. The red line indicates the cut-off of the
CKD model (classification factors above this cut-off are suffering from renal disease). B) Dot-and-line diagram of microalbuminuric patients before
(visit 2) and after two years (visit 9) treatment with 300 mg Irbesartan. Classification factors of all patients, excepting patient no. 34, declined after
Irbesartan intake. C) Box-and-Whisker plot of microalbuminuric patients before (visit 2) and after two years (visit 9) treatment with placebo. D)
Dot-and-line diagram of microalbuminuric patients before (visit 2) and after two years (visit 9) placebo administration.
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analysis of changes in the urinary proteome may also be
useful in evaluation of treatments for other forms of
kidney disease. Of note, drug-induced changes in the
urinary proteome indicating benefit of therapy were
recently reported for ANCA-associated vasculitis [21].
While the data currently available cannot clarify this
issue, further analysis of urine samples from other thera-
peutic trials involving different drugs and other diseases
(glomerulosclerosis and IgA Nephropathy) are planned.
These may help to further support this hypothesis.
A shortcoming of the study reported here is the rela-
tively low number of patients included. Unfortunately,
no additional samples are available from the IRMA2
trial, hence this cannot be improved upon. However,
the results were very consistent within each group.
Even more relevant, we demonstrate on a very low
number of only 11 treated and 11 untreated subjects,
that ARB treatment does have a statistically significant
positive effect, based on the proteomic CKD biomarker
pattern, hence we feel that the report is in agreement
with the recently published guidelines for proteomic
biomarkers [54]. While we cannot exclude the pre-
sence of other confounders or underlying bias, we have
no indication that confounders like e.g. drugs or infec-
tious diseases at the time of sampling had a signifi-
cance impact.
The results highlight an advantage of the urinary pro-
teome analysis: a small number of subjects included in a
trial may be sufficient to reveal significant effects of
drug treatment, based on a classifier that serves as a sur-
rogate marker. While such data can currently not
replace hard endpoints like ESRD, they may serve to
give guidance, e.g. for the decision if a drug may be
likely to exert a positive influence on disease/disease
progression.
Table 1 Significance analysis of CKD markers in urine of microalbuminuric patients before and after
two year treatment
CKD
marker
Sequence Peptide name Wilcoxon
p-value
(Irbesaran
treatment)
Wilcoxon
p-value
(Placebo
intake)
Irbesartan
treatment
Placebo
intake
2505 SpGEAGRpG Collagen alpha-1 (I) chain [522-530] 1.58E-02 n.s. ↑ -
3508 GPpGPpGPpG Collagen alpha-1 (I) chain [145-154] 1.58E-02 n.s. ↑ -
11982 YQTNKAKH Cystatin-B [85-92] 2.55E-03 n.s. ↓ -
13342 ApGDKGESGPS Collagen alpha-1 (I) chain [777-787] 4.46E-02 8.33E-03 ↑↓
14906 MGPRGPpGPpG Collagen alpha-1 (I) chain [217-227] n.s. 1.94E-02 - ↓
15800 GEYKFQNAL Serum albumin
[423-431]
1.53E-03 n.s. ↑ -
17694 ApGDRGEpGPp Collagen alpha-1 (I) chain [798-808] 5.39E-05 n.s. ↑ -
24117 SpGPDGKTGPPGp Collagen alpha-1 (I) chain [546-558] 3.02E-02 1.58E-02 ↑↓
24958 GPpGPDGNKGEpG Collagen alpha-2 (I) chain [613-625] 1.84E-02 n.s. ↑ -
25053 GPpGEAGKpGEQG Collagen alpha-1 (I) chain [650-662] 1.25E-03 n.s. ↑ -
28747 SpGERGETGPpGP Collagen alpha-1 (III) chain [796-808] 4.10E-03 n.s. ↑ -
38780 GLpGTGGPpGENGKpG Collagen alpha-1 (III) chain [642-657] n.s. 2.62E-02 - ↓
55523 SpGSNGApGQRGEpGPQG Collagen alpha-1 (III) chain [358-375] n.s. 4.47E-02 - ↓
61573 DEAGSEADHEGTHSTKR Fibrinogen alpha chain [605-621] 1.92E-02 n.s. ↑ -
73177 DAGApGAPGGKGDAGApGERGPpG Collagen alpha-1 (III) chain [664-687] 7.81E-03 n.s. ↓ -
73697 GNSGEpGApGSKGDTGAKGEPGp Collagen alpha-1 (I) chain [431-453] n.s. 3.51E-02 - ↓
78332 AGPpGEAGKpGEQGVpGDLGAPGP Collagen alpha-1 (I) chain [646-669] 1.04E-02 n.s. ↓ -
81196 NGApGNDGAkGDAGApGAPGSQGApG Collagen alpha-1 (I) chain [700-725] 2.33E-02 n.s. ↓ -
82026 GNSGEpGApGSKGDTGAKGEpGPVG Collagen alpha-1 (I) chain [431-455] 2.71E-02 n.s. ↓ -
94308 TGPIGPpGPAGApGDKGESGPSGPAGPTG Collagen alpha-1 (I) chain [766-794] 1.30E-02 n.s. ↓ -
96370 LmIEQNTKSPLFMGKVVNPTQK Alpha-1-antitrypsin [397-418] 4.47E-02 n.s. ↑ -
118224 ESGREGApGAEGSpGRDGSpGAKGDRGETGPA Collagen alpha-1 (I) chain [1011-1042] n.s. 6.94E-03 - ↓
143947 DQGPVGRTGEVGAVGPpGFAGEKGPSG
EAGTAGPpGTpGPQG
Collagen alpha-2 (I) chain [824-865] 1.59E-03 n.s. ↓ -
Wilcoxon p-values (p < 0.05) of CKD markers, which show changes in the comparison of patients urine before and after longterm treatment are listed. In
addition, sequences and peptide names of the significant markers are shown (p = hydroxyproline, k = hydroxylysine, m = oxidation of methionine). In the last
three columns the regulation of those markers is depicted. Arrow upwards indicates significant change towards “healthy"; arrow pointing down indicates
significant change towards “CKD”.
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The data introduce urinary proteome analysis as a novel
method not only for assessment of new drugs and thera-
peutic regimens in CKD, but also for the treatment
monitoring of patients on renoprotective drugs. Further-
more, the data strengthen the hypothesis that collagens
play an important role in the development of diabetic
nephropathy (see also [53]) and that collagen turnover
m a yb eah i g h l ys u i t a b l et a r g e tf o rd i a g n o s i sa n dn o v e l
therapeutic approaches of this disease.
The proteomic biomarker pattern employed here (the
CKD-273 pattern [20]) may well be a superior surrogate
in comparison to the frequently used assessment of
urinary albumin. To test this hypothesis, UAE and pro-
teomic patterns from samples of longitudinal studies
that reach hard endpoints have to be compared.
Additional material
Additional file 1: Raw data and additional information. Table consists
of 4 different spreadsheets called patients data, classification factor,
polypeptides, and patient’s raw data. Patients data. This table lists
information of each patient, including patients IDs and treatment.
Furthermore urinary albumin concentration, eGFR, and blood pressure
are given at baseline and after two years. Classification factors. Table
show the classification factors of all measured urine samples, including
patients IDs, sample ID, and treatment. Polypeptides. Table listing 2,044
different peptides/proteins (Protein ID) detected, their calibrated
molecular mass [Da], and normalized CE migration time [min].
Furthermore, sequence information is given, if available. Patient’s raw
data. Tables in pivot format show the CE-MS raw data of the 44 samples
in the database. The protein IDs of all peptides are given in the first
column named “Protein ID"; the unique patients IDs constitute the first
row. The MS data from each sample are reflected in one column. The
number in each cell represents the calibrated amplitude of the mass
spectrometric signal of each peptide/protein detected in the sample.
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